Problematising disinformation in breast cancer awareness campaigns.
[Problematising disinformation in breast cancer awareness campaigns]. Gac Sanit. 2017 Feb 02;: Authors: Porroche-Escudero A PMID: 28162756 [PubMed - as supplied by publisher]
Publication date: 15 March 2020Source: Journal of Molecular Structure, Volume 1204Author(s): Puspendu Roy, Deblina Sarkar, Paramita Ghosh, Chandan Kumar Manna, Nabendu Murmu, Tapan Kumar MondalAbstractA new fluorescent Rh(III) cyclometalated complex, [Rh(PPh3)2(L)Cl] (1) is synthesized via sp2(C)–S bond activation of a thioether containing azo-phenol ligand (L-SCH2CH3). The pseudo octahedral geometry around rhodium is confirmed by single crystal X-ray diffraction method. Cyclic voltammogram of the complex exhibits a quasi-reversible oxidation couple with E1/2 of 0.74 V (ΔE = 100 mV) along wi...
Publication date: Available online 10 December 2019Source: Journal of Organometallic ChemistryAuthor(s): Anu Rani, Gurjot Inder Singh, Ramandeep Kaur, Gabriella Palma, Shanen Perumal, Mandeep Kaur, Oluwakemi Ebenezer, Paul Awolade, Parvesh Singh, Vipan KumarAbstractA series of 1H-1,2,3-triazole linked Ferrocenyl-methoxy-methyl-Isatin conjugates was synthesized and assayed for their anti-proliferative activities against estrogen-responsive as well as estrogen non-responsive cell lines. The non-cytotoxic conjugate 7l, with an optimum combination of octyl chain as spacer and methyl-substituent at the C-5 position of isatin, p...
One breast cancer drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat.
ConclusionTargeted axillary dissection is a feasible technique following excellent response to NACT in selected patients with limited volume ALN metastasis, at diagnosis. The identification of the positive ALN during surgery is vital and the IR can be improved by clipping the node prior to NACT and wire guided localisation at the time of surgery.
Condition: Breast Cancer Intervention: Drug: nab-paclitaxel Sponsor: Chinese Academy of Medical Sciences Not yet recruiting
This is a common scenario.1 The goal: maximize freedom from progression but minimize late risks. For a young woman, the main potential late risks secondary to radiation are breast cancer and cardiovascular disease. The main potential late risks from the escalation of chemotherapy are secondary myelodysplastic syndrome and infertility.
An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed.
Roche the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC).
Authors: Darzi S, Mirzaei SA, Elahian F, Shirian S, Peymani A, Rahmani B, Dibazar SP, Aali E Abstract The capability of flavonoids in sensitizing cancer cells was demonstrated in numerous works to chemotherapy and converse multidrug resistance by modulating efflux pumps and apoptosis mechanisms. Three flavonoids, namely, bavachinin, tephrosin, and candidone, have been recently introduced to cancer treatment research presenting various activities, such as antibacterial, immunomodulatory, cell death, and anticancer. Less information exists regarding the therapeutic significance of these flavonoids in cancer treatment...
Although FDG-PET/MRI shows promise for accurate staging of breast cancer, the...Read more on AuntMinnie.comRelated Reading: PET/MRI sheds light on cerebral vascular risk factors PET/MRI can pinpoint causes of chronic extremity pain SNMMI: FDG-PET/MRI improves pain diagnosis, management PET/MRI offers view to atherosclerotic disease origin TOF PET/MRI makes dose reduction viable for breast cancer